Literature DB >> 19952748

Tumor protein 53 mutations and inherited cancer: beyond Li-Fraumeni syndrome.

Edenir I Palmero1, Maria Iw Achatz, Patricia Ashton-Prolla, Magali Olivier, Pierre Hainaut.   

Abstract

PURPOSE OF REVIEW: Germline TP53 (tumor protein 53) mutations are the molecular basis of a complex cancer predisposition syndrome, the Li-Fraumeni syndrome. The present review discusses the diversity of tumor patterns in TP53 mutation carriers, focusing on molecular factors that may explain familial and individual differences, such as genotype/phenotype correlations, genetic modifiers and genetic anticipation. RECENT
FINDINGS: Initially identified 20 years ago, germline TP53 mutations appear to be associated with an extremely diverse range of cancers. Although no other gene has been found in Li-Fraumeni syndrome, recent results show that the functional effects of particular mutations, polymorphisms in TP53 or in regulators such as MDM2 (murine double minute 2), variations in DNA copy number and variations in telomere length, have a strong impact on individual risk and on tumor patterns. Furthermore, recent studies in large cohorts suggest that TP53 germline mutations may occur in up to 1: 5000 individuals.
SUMMARY: Germline TP53 mutations may be responsible for a large fraction (15-20%) of all inherited cancers. Although mutations are detectable by sequencing, counseling and follow-up remain problematic due to the wide variations in disease presentation. Elucidating the molecular mechanisms underlying the predisposition caused by TP53 deficiency may help to develop better, evidence-based and personalized clinical protocols.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19952748     DOI: 10.1097/CCO.0b013e328333bf00

Source DB:  PubMed          Journal:  Curr Opin Oncol        ISSN: 1040-8746            Impact factor:   3.645


  29 in total

Review 1.  [Genes beyond BRCA1 and BRCA2 for hereditary breast cancer].

Authors:  Katharina Simon; Jochen B Geigl; Gunda Pristauz
Journal:  Wien Med Wochenschr       Date:  2010-11

2.  Efficient introduction of specific TP53 mutations into mouse embryonic fibroblasts and embryonic stem cells.

Authors:  Quan-Xiang Wei; Franciscus van der Hoeven; Monica Hollstein; Adam F Odell
Journal:  Nat Protoc       Date:  2012-05-17       Impact factor: 13.491

Review 3.  Towards an understanding of the role of p53 in adrenocortical carcinogenesis.

Authors:  Jonathan D Wasserman; Gerard P Zambetti; David Malkin
Journal:  Mol Cell Endocrinol       Date:  2011-09-10       Impact factor: 4.102

Review 4.  Genetics of Adrenocortical Development and Tumors.

Authors:  Maya Lodish
Journal:  Endocrinol Metab Clin North Am       Date:  2017-02-22       Impact factor: 4.741

5.  A germline variant in the TP53 polyadenylation signal confers cancer susceptibility.

Authors:  Simon N Stacey; Patrick Sulem; Aslaug Jonasdottir; Gisli Masson; Julius Gudmundsson; Daniel F Gudbjartsson; Olafur T Magnusson; Sigurjon A Gudjonsson; Bardur Sigurgeirsson; Kristin Thorisdottir; Rafn Ragnarsson; Kristrun R Benediktsdottir; Bjørn A Nexø; Anne Tjønneland; Kim Overvad; Peter Rudnai; Eugene Gurzau; Kvetoslava Koppova; Kari Hemminki; Cristina Corredera; Victoria Fuentelsaz; Pilar Grasa; Sebastian Navarrete; Fernando Fuertes; Maria D García-Prats; Enrique Sanambrosio; Angeles Panadero; Ana De Juan; Almudena Garcia; Fernando Rivera; Dolores Planelles; Virtudes Soriano; Celia Requena; Katja K Aben; Michelle M van Rossum; Ruben G H M Cremers; Inge M van Oort; Dick-Johan van Spronsen; Jack A Schalken; Wilbert H M Peters; Brian T Helfand; Jenny L Donovan; Freddie C Hamdy; Daniel Badescu; Ovidiu Codreanu; Mariana Jinga; Irma E Csiki; Vali Constantinescu; Paula Badea; Ioan N Mates; Daniela E Dinu; Adrian Constantin; Dana Mates; Sjofn Kristjansdottir; Bjarni A Agnarsson; Eirikur Jonsson; Rosa B Barkardottir; Gudmundur V Einarsson; Fridbjorn Sigurdsson; Pall H Moller; Tryggvi Stefansson; Trausti Valdimarsson; Oskar T Johannsson; Helgi Sigurdsson; Thorvaldur Jonsson; Jon G Jonasson; Laufey Tryggvadottir; Terri Rice; Helen M Hansen; Yuanyuan Xiao; Daniel H Lachance; Brian Patrick O Neill; Matthew L Kosel; Paul A Decker; Gudmar Thorleifsson; Hrefna Johannsdottir; Hafdis T Helgadottir; Asgeir Sigurdsson; Valgerdur Steinthorsdottir; Annika Lindblom; Robert S Sandler; Temitope O Keku; Karina Banasik; Torben Jørgensen; Daniel R Witte; Torben Hansen; Oluf Pedersen; Viorel Jinga; David E Neal; William J Catalona; Margaret Wrensch; John Wiencke; Robert B Jenkins; Eduardo Nagore; Ulla Vogel; Lambertus A Kiemeney; Rajiv Kumar; José I Mayordomo; Jon H Olafsson; Augustine Kong; Unnur Thorsteinsdottir; Thorunn Rafnar; Kari Stefansson
Journal:  Nat Genet       Date:  2011-09-25       Impact factor: 38.330

Review 6.  p53, aerobic metabolism, and cancer.

Authors:  Cory U Lago; Ho Joong Sung; Wenzhe Ma; Ping-yuan Wang; Paul M Hwang
Journal:  Antioxid Redox Signal       Date:  2011-04-14       Impact factor: 8.401

Review 7.  Telomerase and the endocrine system.

Authors:  Furio Pacini; Silvia Cantara; Marco Capezzone; Stefania Marchisotta
Journal:  Nat Rev Endocrinol       Date:  2011-03-29       Impact factor: 43.330

8.  The functional MDM2 T309G genetic variant but not P53 Arg72Pro polymorphism is associated with risk of sarcomas: a meta-analysis.

Authors:  Xu Cai; Ming Yang
Journal:  J Cancer Res Clin Oncol       Date:  2011-12-29       Impact factor: 4.553

9.  Conditional inactivation of p53 in mature B cells promotes generation of nongerminal center-derived B-cell lymphomas.

Authors:  Monica Gostissa; Julia M Bianco; Daniel J Malkin; Jeffery L Kutok; Scott J Rodig; Herbert C Morse; Craig H Bassing; Frederick W Alt
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

Review 10.  Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.

Authors:  April D Sorrell; Carin R Espenschied; Julie O Culver; Jeffrey N Weitzel
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.